Blood test to monitor advanced breast cancer treatment
Part of Cancer, Skin clinical trials.
This study looks at whether a simple blood test can help doctors see how well treatment is working for advanced breast cancer that has stopped responding. It may help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage IV (advanced) breast cancer that is hormone-receptor positive (ER+) and HER2-negative.
- Your cancer is getting worse while on your first line of treatment.
- You feel well enough to be up and about (ECOG 0-2).
- You have not had chemotherapy before.
- You are willing to give blood samples for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a blood test that measures certain markers on cancer cells (CTCs) and genetic material in the blood (cfDNA/RNA) in women with metastatic breast cancer. It aims to better understand the cancer and guide treatment decisions.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study examines tiny particles in your blood from breast cancer cells to better predict which treatments will work best for you. Researchers will collect blood samples and a small tissue sample to understand your cancer's characteristics and help doctors choose more effective therapy.
This trial studies using a blood test to monitor how treatment is working in people with metastatic breast cancer. It may help your care team track your cancer over time with a simpler test.
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
This trial uses a simple blood test to look for two specific gene changes (ESR-1 and gBRCA) in people with hormone receptor-positive, HER2-negative breast cancer that has spread. It aims to detect these mutations earlier and help guide future treatment decisions.
Hear when a new Breast Cancer (Advanced/Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.